Bio Sequence

Biological Glossary | What is Signal Peptide?

9 January 2024
2 min read

A signal peptide (sometimes referred to as signal sequence, targeting signal, localization signal, localization sequence, transit peptide, leader sequence or leader peptide) is a short (3-60 amino acids long) sequence at the front of the protein that directs the protein to specific locations in the cell. It presents at the N-terminus (or occasionally nonclassically at the C-terminus or internally of most newly synthesized proteins that are destined toward the secretory pathway. Signal peptides function like a delivery address, telling the cell where to send the protein for it to function appropriately. They are essential for both membrane-bound and secretory proteins. Once the protein reaches its intended location, the signal peptide is often cleaved off.

Free registration is available for the Bio biological sequence database: https://bio-patsnap-com.libproxy1.nus.edu.sg. Act now to expedite your sequence search tasks.

图片包含 图示

描述已自动生成

Clinical Trial Outcomes Indicate Similar Efficacy Between Alvotech's Biosimilar AVT06 and Its Comparator, Eylea® (Aflibercept)
Latest Hotspot
3 min read
Clinical Trial Outcomes Indicate Similar Efficacy Between Alvotech's Biosimilar AVT06 and Its Comparator, Eylea® (Aflibercept)
9 January 2024
Alvotech, a global biopharma company specializing in biosimilars, reported positive early results from a key trial of AVT06, its candidate similar to Eylea® (aflibercept).
Read →
What is the difference between sustained-release preparations and controlled-release preparations?
"What" Series
2 min read
What is the difference between sustained-release preparations and controlled-release preparations?
9 January 2024
"Sustained-release preparations" are formulations designed for prolonged drug release to maintain enduring effectiveness, often through a first-order release rate.
Read →
OBI Pharma Declares FDA Approval of Investigational New Drug Application for Early-Stage OBI-992 Trial in the U.S
Latest Hotspot
3 min read
OBI Pharma Declares FDA Approval of Investigational New Drug Application for Early-Stage OBI-992 Trial in the U.S
8 January 2024
OBI Pharma announced the FDA has approved its investigational new drug application for OBI-992, allowing the start of a phase 1/2 clinical trial to evaluate their novel TROP2-targeted antibody-drug conjugate for cancer treatment.
Read →
What are AHR agonists and how do you quickly get the latest development progress?
What are AHR agonists and how do you quickly get the latest development progress?
8 January 2024
AHR agonists are drugs that activate the aryl hydrocarbon receptor, used in treating various conditions like psoriasis and dermatitis.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.